| abstract |
Provided are a hybrid of a poorly soluble basic drug and a layered silicate, including a water-soluble basic polymer, and a method of preparing the same. The water-soluble basic polymer may be an aminoalkylmethacrylate copolymer (e.g., Eudragit E 100: a copolymer composed of 1: 2:1 ratio of butyl methacrylate, (2,2-dimethylaminoethyl) methacrylate, and methyl methacrylate, Degussa) or polyvinylacetal diethylaminoacetate (AEA). In an oral formulation including the hybrid, a short-term dissolution of the poorly soluble drug can be increased to 90%, thereby increasing drug bioavailability. |